Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, EK Havrdova, D Horakova… - Journal of Neurology …, 2019 - jnnp.bmj.com
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.
Methods We identified all patients with relapsing-remitting multiple sclerosis treated with
teriflunomide, dimethyl fumarate or fingolimod, with minimum 3-month treatment persistence
and disability follow-up in the global MSBase cohort study. Patients were matched using
propensity scores. Three pairwise analyses compared annualised relapse rates and …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.
Methods We identified all patients with relapsing-remitting multiple sclerosis treated with
teriflunomide, dimethyl fumarate or fingolimod, with minimum 3-month treatment persistence
and disability follow-up in the global MSBase cohort study. Patients were matched using
propensity scores. Three pairwise analyses compared annualised relapse rates and …
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
T Spelman, R Karabudak, E Butler… - Journal of …, 2019 - repository.monashhealth.org
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.
Methods We identified all patients with relapsing-remitting multiple sclerosis treated with
teriflunomide, dimethyl fumarate or fingolimod, with minimum 3-month treatment persistence
and disability follow-up in the global MSBase cohort study. Patients were matched using
propensity scores. Three pairwise analyses compared annualised relapse rates and …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.
Methods We identified all patients with relapsing-remitting multiple sclerosis treated with
teriflunomide, dimethyl fumarate or fingolimod, with minimum 3-month treatment persistence
and disability follow-up in the global MSBase cohort study. Patients were matched using
propensity scores. Three pairwise analyses compared annualised relapse rates and …